Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Johnson & Johnson : J&J, BMS Team Up on Cardiovascular Therapies

share with twitter share with LinkedIn share with facebook
share via e-mail
04/21/2018 | 12:19pm CEST

The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) announced on April 16, 2018 that it has entered a new worldwide collaboration with Bristol-Myers Squibb (BMS) to develop and commercialize Factor XIa (FXIa) inhibitors, including BMS-986177, for preventing and treating major thrombotic conditions.

Under the agreement, Janssen Pharmaceuticals and BMS will advance BMS-986177 into Phase II clinical trials and establish a broad development program across multiple therapeutic indications. The companies will share development costs and commercial profits and losses. Additional terms of the agreement were not disclosed.

Development of next-generation anticoagulants, such as oral anticoagulants, has been a significant step forward in the prevention and treatment of thrombosis, the companies report. The aim with next-generation anticoagulants is to achieve the same efficacy as the current standard of care while substantially lowering the risk of bleeding. FXIa inhibition has been shown in early clinical research to have the potential to reduce the risk of thrombotic events with a significantly lower risk of bleeding compared to currently available therapies, according to the companies.

Janssen has built deep knowledge in the anticoagulation space through our extensive experience researching and developing innovative cardiovascular therapies, said James List, MD, PhD, global therapeutic area head, Cardiovascular and Metabolism, Janssen Research & Development, in a company press release. We look forward to applying our expertise to this collaboration with Bristol-Myers Squibb to explore the full potential of BMS-986177 through Factor XIa inhibition to provide a wider safety window for anticoagulation than current therapies.

With the addition of a Factor XIa inhibitor program to our pipeline, Janssen continues to live up to our long-standing commitment of working tirelessly to bring truly transformational therapies to patients worldwide, said Mathai Mammen, MD, PhD, global head, Janssen Research & Development, in the press release. With this new collaboration we have the potential to improve the standard of care for patients with cardiovascular conditions characterized by pathologic thrombosis.

(c) 2003-2018 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -0.85% 51.17 Delayed Quote.-15.78%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
04/21JOHNSON & JOHNSON : J&J, BMS Team Up on Cardiovascular Therapies
04/20GENMAB : Announces Net Sales of DARZALEX for First Quarter of 2018
04/20JOHNSON & JOHNSON : Reports 2018 First-Quarter Results
04/20JOHNSON & JOHNSON : Janssen Announces Worldwide Development and Commercializatio..
04/20JOHNSON & JOHNSON : Janssen Pharmaceutical - Newly Published Phase 2 Study Found..
04/20JOHNSON & JOHNSON : Small biotech companies dominate the pipeline for Microbiome..
04/20JOHNSON & JOHNSON : Kentucky sues opioid manufacturers
04/20JOHNSON & JOHNSON : BioCentury - BenevolentAI raises $115M
04/19JOHNSON & JOHNSON : - Newly Published Phase 2 study Found Esketamine Demonstrate..
04/19JOHNSON & JOHNSON : Studies offer hope of HIV vaccine
More news
News from SeekingAlpha
04:44aBIOTECH ANALYSIS CENTRAL PHARMA NEWS : J&J Scraps Antibiotic Program, Novartis S.. 
04/22Johnson & Johnson Sells Off After Earnings 
04/21STOCKS TO WATCH : Earnings Blockbusters And Trump Talks Drug Prices 
04/21THE PASSIVE DGI CORE PORTFOLIO : Income, Safety, And Growth 
04/20Rising Inflationary Expectations Cap Equities 
Financials ($)
Sales 2018 81 466 M
EBIT 2018 25 020 M
Net income 2018 16 960 M
Debt 2018 10 657 M
Yield 2018 2,84%
P/E ratio 2018 18,46
P/E ratio 2019 17,17
EV / Sales 2018 4,30x
EV / Sales 2019 4,01x
Capitalization 340 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 145 $
Spread / Average Target 14%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
AMGEN-1.35%114 648